? The Radiation Therapy Oncology Group (RTOG) is committed to its role as a Research Base for the Community Clinical Oncology Program (CCOP). This application documents the progress and future plans of the RTOG Cancer Prevention and Control (CPC) program including the development of CPC clinical trials and oversight of CCOP participation in the Group's cancer treatment studies. This application also documents the involvement of RTOG's non-CCOP members in CPC studies. ? ? The major focus of RTOG's CPC program is the development of protocols to evaluate novel interventions that decrease or prevent treatment-related acute and late toxicities. These studies reflect the principle that a decrease in toxicity can allow more aggressive therapy and improve outcome. The CPC program is also charged to reduce patient suffering through improved palliation, reduced late tissue effects and a reduced rate of second malignancies. Since the majority of radiotherapy patients are treated in the community setting, CCOP members are essential to the successful implementation of the CPC program. The participation of community-based investigators has also afforded RTOG the opportunity to observe how well new therapies and new technologies, such as radiosurgery and intensity modulated radiation therapy (IMRT), can transfer to the community and for CCOP members to evaluate their effectiveness and morbidity. ? ? This application divides the proposed CPC activities into four sections: interventions to decrease patient suffering symptom management; prevention and reduction of late effects to cancer therapy; chemoprevention of second malignancies; and, integrative oncology - complementary and alternative medicine (CAM). The symptom management studies will continue to dominate the CPC activities; the late effects program will study the role of cytokine profiles in predicting late effects; the chemoprevention program will address the potential of a Cox-2 inhibitor as a chemoprevention agent; and the integrative oncology program will continue to conduct rigorous controlled studies to document the effectiveness of CAM for radiation therapy patients. ? ? The CPC program is directed by the RTOG Vice-Chair for CPC, as well Chairs for each section and a CPC Steering Committee. The CCOP Membership Committee evaluates the CCOPs to assure adherence to all NCI requirements. The RTOG Administrative, Protocol Development and Regulatory Compliance, Quality Assurance, Data Management, and Statistical Units are utilized in the development and monitoring of CPC trials, and RTOG quality assurance procedures, including on-site audits, are applied to the CCOPs. The goal of the RTOG CCOP program is to design and implement CDC studies and to integrate community institutions into RTOG's scientific program. ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA037422-18
Application #
6925761
Study Section
Special Emphasis Panel (ZCA1-SRRB-D (J1))
Program Officer
O'Mara, Ann M
Project Start
1994-06-01
Project End
2010-05-31
Budget Start
2005-08-15
Budget End
2006-05-31
Support Year
18
Fiscal Year
2005
Total Cost
$1,665,537
Indirect Cost
Name
American College of Radiology
Department
Type
DUNS #
062485800
City
Reston
State
VA
Country
United States
Zip Code
20191
Dormer, James D; Ma, Ling; Halicek, Martin et al. (2018) Heart Chamber Segmentation from CT Using Convolutional Neural Networks. Proc SPIE Int Soc Opt Eng 10578:
Michalski, Jeff M; Moughan, Jennifer; Purdy, James et al. (2018) Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer: The NRG Oncology RTOG 0126 Randomized Clinical Trial. JAMA Oncol 4:e180039
Seider, Michael J; Pugh, Stephanie L; Langer, Corey et al. (2018) Randomized phase III trial to evaluate radiopharmaceuticals and zoledronic acid in the palliation of osteoblastic metastases from lung, breast, and prostate cancer: report of the NRG Oncology RTOG 0517 trial. Ann Nucl Med 32:553-560
Basch, Ethan; Dueck, Amylou C; Rogak, Lauren J et al. (2018) Feasibility of Implementing the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in a Multicenter Trial: NCCTG N1048. J Clin Oncol :JCO2018788620
Regine, William F; Winter, Kathryn; Abrams, Ross A et al. (2018) Postresection CA19-9 and margin status as predictors of recurrence after adjuvant treatment for pancreatic carcinoma: Analysis of NRG oncology RTOG trial 9704. Adv Radiat Oncol 3:154-162
Konski, Andre; Bhargavan, Mytheryi; Owen, Jean et al. (2018) An Economic Analysis of Radiation Therapy Oncology Group 94-10: Cost-Efficacy of Concurrent vs. Sequential Chemoradiotherapy. J Radiat Oncol 7:195-201
Small Jr, William; James, Jennifer L; Moore, Timothy D et al. (2018) Utility of the ACE Inhibitor Captopril in Mitigating Radiation-associated Pulmonary Toxicity in Lung Cancer: Results From NRG Oncology RTOG 0123. Am J Clin Oncol 41:396-401
Ali, Arif N; Zhang, Peixin; Yung, W K Alfred et al. (2018) NRG oncology RTOG 9006: a phase III randomized trial of hyperfractionated radiotherapy (RT) and BCNU versus standard RT and BCNU for malignant glioma patients. J Neurooncol 137:39-47
Lawrence, Yaacov R; Moughan, Jennifer; Magliocco, Anthony M et al. (2018) Expression of the DNA repair gene MLH1 correlates with survival in patients who have resected pancreatic cancer and have received adjuvant chemoradiation: NRG Oncology RTOG Study 9704. Cancer 124:491-498
Raman, Srinivas; Ding, Keyue; Chow, Edward et al. (2018) Minimal clinically important differences in the EORTC QLQ-C30 and brief pain inventory in patients undergoing re-irradiation for painful bone metastases. Qual Life Res 27:1089-1098

Showing the most recent 10 out of 326 publications